Ultragenyx is the older company (2013 vs 2010); Ultragenyx is the larger of the two.
Side-by-Side Comparison
| Metric | Solid Biosciences | Ultragenyx |
|---|---|---|
| Founded | ||
| Founded | 2013 | 2010 older |
| Headquarters | ||
| Headquarters | Boston, United States | Novato, United States |
| Employees | ||
| Employees | 161 | 1535 larger |
| Industry | ||
| Industry | Biotechnology, Health Care | Biotechnology, Health Care, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $610.30M | $1.14B |
| Funding Rounds | ||
| Funding Rounds | 9 | 6 |
| Services | ||
| Services | Gene Therapy Development, Clinical Trials, Research Collaborations, Licensing Opportunities, Manufacturing Infrastructure | Development of therapies for rare genetic diseases, Gene therapy solutions, Clinical trials and transparency, Drug modality exploration, Patient advocacy and support |
| Target Customers | ||
| Target Customers | Patients with Rare Neuromuscular Diseases, Patients with Cardiac Diseases, Medical Researchers, Healthcare Providers, Biotechnology Collaborators | Patients with rare and ultra-rare diseases, Healthcare professionals, Patient advocacy groups, Medical researchers, Healthcare investors |
| Taxonomy | ||
| Taxonomy | Precision Genetic Medicine, Gene Therapy, Rare Neuromuscular Diseases, Cardiac Diseases, Duchenne Muscular Dystrophy, Friedreich’s Ataxia, Catecholaminergic Polymorphic Ventricular Tachycardia, Dilated Cardiomyopathy, Genetic Regulators, Gene Therapy Delivery, Dystrophin Protein Restoration, Orphan Drug Designation, Rare Pediatric Disease Designation, Preclinical Program, Phase I/II Clinical Trial | Rare Diseases, Ultrarare Diseases, Orphan Drugs, Genetic Diseases, Therapeutics Development, Clinical Pipeline, Innovative Medicines, Transformative Therapies, Unmet Medical Needs, Inclusive Culture, Patient-focused, Drug Commercialization, Scientific Research, Product Portfolio |
| Website | ||
| Website | solidbio.com | ultragenyx.com |
About Solid Biosciences
Solid Biosciences, founded in 2013 and headquartered in Charlestown, MA, USA, is a trailblazer in the biotechnology sector, especially in precision genetic medicine. Their motto, #TogetherWeAreSolid, reflects their commitment to advancing gene therapy solutions for rare neuromuscular and cardiac dis...
About Ultragenyx
Ultragenyx, founded in 2010 and headquartered in the United States, is making significant strides in the Biotechnology, Health Care, and Pharmaceutical sectors. With the slogan "Going Beyond Every Day," the company is dedicated to developing innovative therapies for rare and ultra-rare diseases, aim...
We will tell you when either one moves
BounceWatch watches Solid Biosciences and Ultragenyx for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Solid Biosciences and Ultragenyx — by email.
Frequently Asked Questions
Compare Solid Biosciences with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Solid Biosciences on 9 Jun 2026, and Ultragenyx on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.